Risdiplam — Membership Pricing
Risdiplam is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Risdiplam Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $473.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Risdiplam
Risdiplam is a prescription medication. Ask your doctor if Risdiplam is right for you.
How to Check Risdiplam Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Risdiplam at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Neurological
About Risdiplam
Spinal Muscular Atrophy (SMA) is a rare, genetic neuromuscular disorder characterized by the loss of motor neurons and progressive muscle wasting. This can lead to difficulties with breathing, swallowing, and movement. Risdiplam (Evrysdi) represents a significant advancement in SMA treatment, offering an oral, liquid medication option for adults and children 2 months of age and older diagnosed with SMA.
How Risdiplam Works
Risdiplam works by increasing the production of functional survival motor neuron (SMN) protein. In individuals with SMA, there's a deficiency of this protein due to a genetic mutation. Risdiplam modifies the splicing of the SMN2 gene, a 'backup' gene that typically produces only a small amount of functional SMN protein. By enhancing the SMN2 gene's ability to create more functional SMN protein, risdiplam helps to improve motor function and reduce disease progression. Its oral administration offers a convenient alternative to other SMA treatments that require injections or infusions.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Risdiplam is approved for (FDA label)
EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: February 19, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Risdiplam (FDA label)
EVRYSDI for oral solution: 60 mg as a light yellow, pale yellow, yellow, greyish yellow, greenish yellow, or light green powder for constitution. Following constitution, the volume of the greenish yellow to yellow solution is 80 mL, providing 60 mg/80 mL (0.75 mg/mL) risdiplam. EVRYSDI tablet: 5 mg as a pale yellow film-coated tablet, round and curved, with EVR debossed on one side. For Oral Solution: 60 mg of risdiplam as a powder for constitution to provide 0.75 mg/mL solution. ( 3 ) Tablets: 5 mg
Source: FDA prescribing information (DailyMed). Set ID: eceb9a99-7191-4be5-87c3-0102707cf98e. SPL document ID: a0597961-b4b9-47ec-961a-919fa9ffba95. Label effective date: February 19, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Risdiplam (FDA label)
The most common adverse reactions in later-onset SMA (incidence at least 10% of patients treated with EVRYSDI and more frequent than control) were fever, diarrhea, and rash. ( 6.1 ) The most common adverse reactions in infantile-onset SMA were similar to those observed in later-onset SMA patients.
Source: FDA prescribing information (DailyMed). Set ID: eceb9a99-7191-4be5-87c3-0102707cf98e. SPL document ID: a0597961-b4b9-47ec-961a-919fa9ffba95. Label effective date: February 19, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Risdiplam (FDA label)
None. None. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: eceb9a99-7191-4be5-87c3-0102707cf98e. SPL document ID: a0597961-b4b9-47ec-961a-919fa9ffba95. Label effective date: February 19, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Risdiplam (FDA label)
Avoid coadministration with drugs that are substrates of multidrug and toxin extrusion (MATE) transporters. ( 7.1 ) 7.1 Effect of EVRYSDI on Substrates of Multidrug and Toxin Extrusion (MATE) Protein Transporters Based on in vitro data, EVRYSDI may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K [see Clinical Pharmacology (12.3) ] , such as metformin. Avoid coadministration of EVRYSDI with MATE substrates. If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction of the coadministered drug (based on the labeling of that drug) if needed.
Source: FDA prescribing information (DailyMed). Set ID: eceb9a99-7191-4be5-87c3-0102707cf98e. SPL document ID: a0597961-b4b9-47ec-961a-919fa9ffba95. Label effective date: February 19, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.